Trial Results Show Impressive Benefit of Carfilzomib (Kyprolis®) versus Bortezomib (Velcade®) in Relapsed Myeloma

This week’s news of interim results from the ENDEAVOR trial, a head-to-head comparison of “real world” schedules of Kyprolis versus Velcade, reveals an impressive benefit of carfilzomib over bortezomib in relapsed myeloma. Indeed, the 929-patient phase III trial showed a progression-free survival (PFS) of 18.7 months for Kyprolis versus 9.4 months for Velcade—basically a doubling of PFS or remission duration.

Pomalidomide Update

The US Food and Drug Administration (FDA) has cancelled the planned November advisory committee (ODAC) meeting for Celgene's pomalidomide application.  Celgene, in a press release, indicated that the pomalidomide application is continuing, which means that a decision with regard to pomalidomide is still expected on or before February 10, 2013.